Our results demonstrate that stage I MYC-R patients, including those with DH/TH disease, have an excellent survival outcome comparable to patients without a MYC rearrangement, which is in line with a previous report involving limited-stage DH DLBCL [14]. This evidence concerns the gene MYC and diffuse large B-cell lymphoma.